Skip Nav Destination
1-20 of 22
Kenshi Suzuki, Kazutaka Sunami, Morio Matsumoto, Akio Maki, Fumika Shimada, Kazuyuki Suzuki, Kazuyuki Shimizu
Acta Haematol (2021) 144 (3): 264–274.
Published Online: 04 December 2020
...Kenshi Suzuki; Kazutaka Sunami; Morio Matsumoto; Akio Maki; Fumika Shimada; Kazuyuki Suzuki; Kazuyuki Shimizu Introduction: Panobinostat, bortezomib, and dexamethasone combination therapy demonstrated progression-free survival (PFS) benefit over bortezomib and dexamethasone alone in the PANORAMA-1...
Iván Murrieta-Álvarez, David P. Steensma, Juan Carlos Olivares-Gazca, Mauricio Olivares-Gazca, Andrés León-Peña, Yahveth Cantero-Fortiz, Yarely Itzayana García-Navarrete, Antonio Cruz-Mora, Alejandro Ruiz-Argüelles, Guillermo José Ruiz-Delgado, Guillermo José Ruiz-Argüelles
Acta Haematol (2020) 143 (6): 552–558.
Published Online: 11 February 2020
.... The response rate (complete remission or very good partial remission) was 72% for those given thalidomide plus dexamethasone versus 88% for those given bortezomib, thalidomide, and dexamethasone before HCT, but OS was not different. As post-HCT maintenance, 37 patients received thalidomide; 26 of those (70...
Acta Haematol (2020) 143 (2): 146–154.
Published Online: 21 August 2019
... setting, the combination of intravenous bortezomib and oral vorinostat (BV) was studied and showed efficacy. Therefore, it was reasonable to study this combination therapy post-ASCT. Patients and Methods: We report on BV given post-ASCT. All 30 patients underwent conditioning for ASCT with high-dose...
Keisuke Tanaka, Shigeo Toyota, Megumi Akiyama, Naoki Wakimoto, Yuichi Nakamura, Yuho Najima, Noriko Doki, Kazuhiko Kakihana, Aiko Igarashi, Takeshi Kobayashi, Kazuteru Ohashi, Daisuke Kudo, Atsushi Shinagawa, Hina Takano, Takayuki Fujio, Yasushi Okoshi, Mitsuo Hori, Takashi Kumagai, Tatsuya Saito, Junichi Mukae, Koh Yamamoto, Ikuyo Tsutsumi, Takuya Komeno, Chikashi Yoshida, Masahide Yamamoto, Hiroshi Kojima, on behalf of the Ochanomizu Hematology Study Group
Acta Haematol (2019) 141 (2): 111–118.
Published Online: 06 February 2019
...; Junichi Mukae; Koh Yamamoto; Ikuyo Tsutsumi; Takuya Komeno; Chikashi Yoshida; Masahide Yamamoto; Hiroshi Kojima; on behalf of the Ochanomizu Hematology Study Group We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell...
Acta Haematol (2018) 140 (4): 209–214.
Published Online: 19 October 2018
...Boaz Nachmias; Adir Shaulov; Moshe E. Gatt; Michael Shapira; Alexander Gural The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine...
Acta Haematol (2018) 140 (1): 46–50.
Published Online: 16 August 2018
... was diagnosed as suffering from nonsecretory multiple myeloma (MM) complicated by acquired factor X deficiency. A complete response (CR) of the myeloma and recovery of factor X activity (56.6%) were achieved after the administration of treatment, including chemotherapy and bortezomib. We suggest that patients...
Alessia Bari, Raffaella Marcheselli, Luigi Marcheselli, Isabel Alvarez, Samantha Pozzi, Paola Ferri, Antonio Lazzaro, Alberto Fragasso, Santo Neri, Luca Baldini, Angelo Michele Carella, Francesco Angrilli, Roberto Guariglia, Gabriele Buda, Caterina Stelitano, Stefano Sacchi, on behalf of the Gruppo Italiano Studio Linfomi (GISL)
Acta Haematol (2017) 137 (1): 7–14.
Published Online: 01 January 2017
... Italiano Studio Linfomi (GISL) Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma. On the basis of these findings, we performed a phase II study of B combined with rituximab (R) in patients with relapsed follicular lymphoma (FL). Forty...
Acta Haematol (2016) 136 (3): 140–146.
Published Online: 14 July 2016
... was conducted that included 68 patients treated in the last 10 years, 37 of whom received bortezomib only (bortezomib group), 13 of whom received bortezomib and underwent autologous hematopoietic stem cell transplantation (bortezomib + ASCT group), and 18 of whom received conditional chemotherapy (non...
Acta Haematol (2015) 134 (4): 229–230.
Published Online: 11 June 2015
...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Bortezomib Dexamethasone Multiple myeloma The results of the VISTA (Velcade as Initial Standard Therapy...
Yukiko Cho, Mitsuo Hori, Yasushi Okoshi, Fumie Fujisawa, Atsushi Shinagawa, Daisuke Kudo, Takuya Komeno, Chikashi Yoshida, Yukitaka Katsura, Ikuyo Ota, Seiichi Shimizu, Masaharu Kamoshita, Katsuhiro Sasaki, Keiji Tanaka, Harumi Y. Mukai, Hiroshi Kojima, Ibaraki Hematology Oncology Palliation Expert Party (IB-HOPE)
Acta Haematol (2015) 134 (1): 25–31.
Published Online: 03 April 2015
... Party (IB-HOPE) Aims: To explore the biomarker for predicting the occurrence of adverse events in myeloma patients treated by intravenous bortezomib, we measured proteasome activity in peripheral blood mononuclear cells. Methods: Samples were obtained from 34 bortezomib-naïve patients. Proteasome...
Moo-Kon Song, Joo-Seop Chung, Je-Jung Lee, Jae-Hoon Lee, Ik-Chan Song, Sang-Min Lee, Dong-Yeop Shin, Gyeong-Won Lee, In-Sook Lee
Acta Haematol (2015) 134 (1): 7–16.
Published Online: 28 March 2015
... not eligible for transplantation. The initial treatment regimen was therapy with melphalan-prednisone (MP, n = 44), thalidomide-cyclophosphamide-dexamethasone (n = 89) or bortezomib-MP (VMP, n = 65). The magnetic resonance imaging (MRI) pattern was normal in 34 patients, focal in 30 and diffuse/variegated...
Daisuke Ohgiya, Takahide Tsuchiya, Takahiro Suyama, Shigeki Watanabe, Hiroki Numata, Kosuke Tsuboi, Tamotsu Sasao
Acta Haematol (2014) 133 (1): 29–30.
Published Online: 01 July 2014
... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Multiple myeloma Bortezomib...
Shuji Ozaki, Takeshi Harada, Takayuki Saitoh, Chihiro Shimazaki, Mitsuhiro Itagaki, Hideki Asaoku, Yoshiaki Kuroda, Takaaki Chou, Yumiko Yoshiki, Kenshi Suzuki, Hirokazu Murakami, Kunihiko Hayashi, Roberto Mina, Antonio Palumbo, Kazuyuki Shimizu, on behalf of the Japanese Society of Myeloma and the European Myeloma Network
Acta Haematol (2014) 132 (2): 211–219.
Published Online: 22 March 2014
... and the European Myeloma Network Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents improve the prognosis of elderly patients who have undergone autologous stem cell transplantation...
Acta Haematol (2013) 129 (4): 207–214.
Published Online: 15 May 2013
... are urgently needed. Bortezomib (Velcade, formerly PS-341) is the first proteasome inhibitor approved by the US FDA for the treatment of newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma and mantle cell lymphoma. Although the mechanisms of bortezomib anticancer activity are still...
Acta Haematol (2013) 129 (2): 101–105.
Published Online: 21 November 2012
...Ke Zeng; Jin-rong Yang; Jun Li; Qing Wei; Yi-ming Yang; Ting Liu; Ting Niu POEMS syndrome is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes. Bortezomib is an important component of the chemotherapy regimen associated with multiple myeloma...
Acta Haematol (2012) 128 (4): 244–247.
Published Online: 04 September 2012
...Margarita Bockorny; Saneka Chakravarty; Peter Schulman; Bruno Bockorny; Robert Bona Background: Bortezomib is a novel, first-in-class peptide which reversibly inhibits the proteasome and is Food and Drug Administration approved for the treatment of multiple myeloma, non-Hodgkin lymphoma...
Acta Haematol (2011) 126 (3): 163–168.
Published Online: 29 September 2011
...Eugenio Piro; Stefano Molica This report presents the totality of evidence through a systematic review that assessed either the efficacy or safety of bortezomib-based regimens in multiple myeloma with renal impairment. A systematic and comprehensive search of the literature was performed using...
Moo-Kon Song, Joo-Seop Chung, Young-Don Joo, Sang-Min Lee, Gyeong-Won Lee, Ho-sup Lee, Sung-Hyun Kim, Eun-Young Yun, Young-Mi Seol, Seung-Geun Kim, Ho-Jin Shin, Young-Jin Choi, Goon-Jae Cho
Acta Haematol (2010) 124 (1): 34–39.
Published Online: 03 July 2010
... in newly diagnosed multiple myeloma (MM). Recent studies showed tumor sensitization and enhanced cytotoxicity of bortezomib. We hypothesized that a high ALC before bortezomib treatment would contribute to tumor sensitization and activated cytotoxicity of bortezomib in relapsed MM. Ninety-seven relapsed MM...
Concetta Conticello, Luana Adamo, Luisa Vicari, Raffaella Giuffrida, Gioacchin Iannolo, Gabriele Anastasi, Laura Caruso, Gaetano Moschetti, Alessandra Cupri, Giuseppe Antonio Palumbo, Massimo Gulisano, Ruggero De Maria, Rosario Giustolisi, Francesco Di Raimondo
Acta Haematol (2008) 120 (1): 19–30.
Published Online: 21 August 2008
...) is a malignant disease characterized by abnormal proliferation of clonal precursor cells. Although different strategies have been adopted to obtain complete remission, the disease actually progresses in about 60–70% of patients. Bortezomib has been used in multiple myeloma and other lymphoid malignancies because...
Sung-Jin Moon, Chang-Ki Min, Dong-Gun Lee, Seok Lee, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim, Myungshin Kim, Gyeongsin Park, Younggu Kim
Acta Haematol (2007) 117 (4): 211–214.
Published Online: 18 January 2007
...Sung-Jin Moon; Chang-Ki Min; Dong-Gun Lee; Seok Lee; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim; Myungshin Kim; Gyeongsin Park; Younggu Kim The proteasome inhibitor, bortezomib, has antimyeloma activity even in myeloma cells refractory to multiple prior treatments. The most commonly reported...